Drugs / L1-79
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02796898 | Jun 2016 → May 2019 | prostate cancer | Tyme, Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05067582 | Jan 2022 → Jun 2024 | autism | Yamo Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 2 | NCT02947048 | Oct 2016 → Dec 2017 | autism | Yamo Pharmaceuticals LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L1-79 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02947048 ↗ |
| Known as | Racemetyrosine | “Racemetyrosine (SM-88) is an amino-acid analogue used with methoxsalen, phenytoin, and sirolimus (MPS) to enhance SM-88 activity.” PMID 32924093 ↗ Sep 2020 |
| Action | Inhibit | “tyrosine hydroxylase inhibitor” NCT05067582 ↗ |
| Modality | Other / unclassified | “Racemetyrosine (SM-88) is an amino-acid analogue used with methoxsalen, phenytoin, and sirolimus (MPS) to enhance SM-88 activity.” PMID 32924093 ↗ Sep 2020 |
| Route | Oral | “1 capsule twice daily” NCT05067582 ↗ |